Comprehensive Cancer Panel Comp Cancer

Synonyms

Allscripts (AEHR) Order Name

Comprehensive Cancer Panel

Sunrise Clinical Manager (SCM) Order Name

Not Orderable

EPIC Order Name

Comprehensive Cancer Panel

Clinical Info

This test is appropriate when the patient's differential diagnosis includes various hereditary
cancer syndromes.
The Comprehensive Cancer panel offers increased clinical sensitivity
compared to testing for a few genes at a time since it tests for multiple syndromes at
once across multiple cancer types. Molecular diagnosis may help in determining
treatment and management, as well as identification of at risk family members.

Specimen Type

Blood

Container

Lavender Top Tube

Collection Instructions

Container/Tube: Lavender top tube
Specimen: 2 - 5 mL whole blood
Transport Temperature: Room Temperature

Note: Clinical Information required for complete interpretation
Alternate sample type: DNA: Extract and submit DNA 50 ng/mL
(total volume 400 mL) in sterile container. Ship DNA in sealed
and protective packaging at ambient temperature, using a cool
pack in hot weather. Labeling: Name of person or identifier,
DNA concentration and volume MUST be provided on the specimen tube.

Transport Instructions

Room Temperature

Specimen Stability

7 Days RefrigeratedBlood samples older than 7 days can still be shipped, they will be tested if the yield and quality of DNA permit.

Methodology

Deletion/Duplication Analysis
Next-Gen Sequencing

Days Performed

TAT: 2 Weeks
This test is appropriate when the patient's differential diagnosis includes various hereditary
cancer syndromes. For example, if the family history consists of multiple cases of ovarian
cancer, this may be associated with a breast/ovarian cancer syndrome such as BRCA1 or BRCA2 or Lynch syndrome
(MLH1, MSH2, MSH6, PMS2, EPCAM). This test may be
appropriate when the patient family history includes a number of cancer cases, but they
are of several different types, the pattern does not seem to fit any one hereditary cancer syndrome in particular, or if some
genetic testing has already been ordered due to a
family history suggestive of a hereditary cancer predisposition but all results have
been negative. The Comprehensive Cancer panel offers increased clinical sensitivity
compared to testing for a few genes at a time since it tests for multiple syndromes at
once across multiple cancer types. Molecular diagnosis may help in determining
treatment and management, as well as identification of at risk family members.

Performing Laboratory

GeneDx (B275)

CPT

81433
81432 (HBOC diagnosis)
81435
81436 (non-HBOC diagnosis)

PDM

1659841

Result Interpretation

See Report
Includes Genes: APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, CTNNA1, EPCAM, FANCC, FANCM, FH, FLCN, HOXB13, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, POT1, PTEN, RAD51C, RAD51D, RECQL, SCG5 (GREM1), SDHB, SDHC, SDHD, SMAD4, STK11, TP53, TSC1, TSC2, VHL
 
 

Forms

edit